This article will address RU-28362 from a broad and detailed approach, with the aim of providing the reader with a complete and in-depth vision of this topic. Its origins, evolution and relevance today will be explored, as well as its implications in different areas. Different perspectives, expert opinions and relevant data will be analyzed that will allow the reader to comprehensively understand RU-28362. In addition, case studies and concrete examples will be presented that will illustrate the importance and impact of RU-28362 in today's society. Through this article, we seek to offer an informed and enriching perspective on RU-28362, which invites reflection and debate.
![]() | |
Names | |
---|---|
IUPAC name
11β,17β-Dihydroxy-6-methyl-17α-(prop-1-yn-1-yl)androsta-1,4,6-trien-3-one
| |
Systematic IUPAC name
(1S,3aS,3bS,9aR,9bS,10S,11aS)-1,10-Dihydroxy-5,9a,11a-trimethyl-1-(prop-1-yn-1-yl)-1,2,3,3a,3b,9a,9b,10,11,11a-decahydro-7H-cyclopentaphenanthren-7-one | |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C23H28O3 | |
Molar mass | 352.474 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
|
RU-28362 is a synthetic androstane glucocorticoid that was developed by Roussel Uclaf. It is a selective agonist of the glucocorticoid receptor (corticoid type II receptor), but not of the mineralocorticoid receptor (corticoid type I receptor).[1][2]
A similar compound is dexamethasone that also selectively binds to the glucocorticoid receptor with high affinity. This is in contrast to the natural steroid hormones cortisol or corticosterone, which bind to both of the corticosteroid receptors, though they bind to the mineralocorticoid receptor with greater affinity.[3]